Nacho Abia - Grifols SA CEO Director

GRFS Stock  USD 8.07  0.65  7.45%   

CEO

Nacho Abia is CEO Director of Grifols SA ADR
Age 56
Address Avinguda de la Generalitat, 152, Barcelona, Spain, 08174
Phone34 935 712 200
Webhttps://www.grifols.com

Grifols SA Management Efficiency

The company has return on total asset (ROA) of 0.0287 % which means that it generated a profit of $0.0287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0271 %, meaning that it created $0.0271 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0 in 2024. Return On Capital Employed is likely to drop to 0.04 in 2024. At this time, Grifols SA's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 15.7 B in 2024, whereas Net Tangible Assets are likely to drop (2.1 B) in 2024.
Grifols SA ADR currently holds 10.12 B in liabilities with Debt to Equity (D/E) ratio of 1.14, which is about average as compared to similar companies. Grifols SA ADR has a current ratio of 2.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Grifols SA's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 8 records

CEO Age

Brian McNamaraGlaxoSmithKline PLC ADR
49
Pascal SoriotAstraZeneca PLC ADR
60
Deborah WaterhouseGlaxoSmithKline PLC ADR
N/A
William AndersonRoche Holding Ltd
57
Severin SchwanRoche Holding Ltd
56
Richard SaynorNovartis AG ADR
57
Emma WalmsleyGlaxoSmithKline PLC ADR
55
Christopher ViehbacherBiogen Inc
63
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company was founded in 1940 and is headquartered in Barcelona, Spain. Grifols SA operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 27584 people. Grifols SA ADR (GRFS) is traded on NASDAQ Exchange in USA. It is located in Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 and employs 23,000 people. Grifols SA is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Grifols SA ADR Leadership Team

Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Camille Alpi, Chief Officer
Alberto Roura, President Division
Jose Buenache, CEO Director
Thomas Glanzmann, Executive Chairman
Alfredo Guerra, CFO and Corporate VP
Raimon Roura, Non-Member Secretary of the Board
Miguel Montblanch, President Support
Alfredo CPA, CFO VP
Nuria Lapea, Risk Treasury
Sergio Adell, President Support
Maria Llano, Chief Officer
M Tubau, Corporate Affairs
Vicente Torre, Chief Officer
Steven JD, Ex Chairman
Nacho Abia, CEO Director
Mateo Humbert, Director of Human Resources
Montserrat Llamas, Chief Officer
Vctor Deu, Executive Director
Lluis Gomez, Senior Office
David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries

Grifols Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Grifols Stock Analysis

When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.